number of hematopoietic progenitor cells, and more rapid neutrophil and platelet engraftment. 4 An important clinical issue in allo-PBPCT is the engraftment potential of the Peripheral blood progenitor cells (PBPC) are increasingly being used to perform allogeneic transplants (allo-PBPC and, particularly, whether these cells are capable of long-term hematopoietic repopulation. Studies in murine PBPCT). An important issue regarding allo-PBPCT is the potential for long-term engraftment of human models have demonstrated that hematopoietic cells mobilized into peripheral blood with G-CSF are able to maintain PBPC. A subset of bone marrow (BM) cells displaying the immunophenotype CD34
6,7
In humans, the question of long-term engraftment of alloproperties associated with pluripotential stem cells. We studied the origin (donor vs recipient) of CD34 ؉ HLAgeneic PBPC has been mainly addressed by studying the hematopoietic chimerism in the peripheral blood of patients DR ؊ hematopoietic cells from patients having received allo-PBPCT and with a long follow-up (14؉ to 21؉ receiving allo-PBPCT. In addition, the absence of late graft failure is in favor of sustained hematopoietic engraftmonths). Chimeric status was determined after amplification by polymerase chain reaction (PCR) of short ment. [1] [2] [3] 5 However, no data have been reported regarding the existence of early progenitor cells, such as CD34 In all cases the follow-up was longer than 1 year (between 14 and 21 months). All of them had hematologic maligKeywords: peripheral blood progenitor cells; chimerism; allogeneic transplantation; CD34 ϩ HLA-DR Ϫ cells nancies: three were diagnosed with acute myeloid leukemia (M3 subtype, according to FAB classification) in second complete remission, and one with an acute lymphoid leukemia with a t(9;22) in first complete remission. Age, sex, G-CSF-mobilized PBPC are being increasingly used as a disease status, conditioning regimen, number of CD34 ϩ source of hematopoietic cells for allogeneic transplancells and CD3 ϩ cells administered, outcome, and maximum tation. [1] [2] [3] [4] [5] Allogeneic peripheral blood progenitor cells transfollow-up are detailed in Table 1 . Patients and donors gave plants (allo-PBPCT) have two major advantages over bone informed consent to enter into the study, and clinical protomarrow (BM) transplants, namely: safer collection of a high cols were approved by the Ethical Committee of the hospital, and by the Spanish Health Department. Three patients were conditioned with cyclophosphamide 
10
Bone marrow samples Briefly, the suspension containing the sorted cells was col-BM aspirates were performed at 21, 17, 16 and 14 months lected directly into reaction tubes. One milliliter of sterile after transplant, respectively. Samples were collected into water was added and centrifuged at 13 000 r.p.m. for 3 min. a tube containing heparin and kept at room temperature All, except 20 l, of the supernatant was discharged and until the time of analysis, which was performed within the replaced with 60 l of 5% (w/v) Chelex resin. The mixture same day of collection in all cases.
was incubated at 56°C for 15 min, vortexed, and boiled for 8 min. Afterwards, the sample was vortexed again and centrifuged at 13 000 r.p.m. for 3 min. The supernatant Immunological staining of BM samples obtained was used for PCR amplification of STR Samples were stained by direct immunofluorescence using sequences. a triple-staining combination of HLA-DR, CD34, and CD38 monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE) and PE/cyanine STR 5 (PE/Cy5), respectively. HLA-DR and CD34 reagents Chimerism analysis was done using PCR amplification of were purchased from Becton Dickinson (BD) (San José, STR (PCR-STR). A panel of four STRs (vWF, intron 40; CA, USA), and CD38 from Caltag Laboratories (San Fran-HUMTH01; FES-FPS; and F13A1) was used to detect ciso, CA, USA). The procedure has been previously genotypic differences between donor and recipient pairs described. 8 Briefly, 200 l of BM sample containing before transplant. After transplant, the STR which was approximately 1 ϫ 10 7 nucleated cells were incubated for informative for the donor-recipient pair was used for the 15 min at room temperature with the monoclonal antibodies assessment of the chimeric status. mentioned above. Afterwards, erythrocytes were lysed by incubating the cells for 10 min at room temperature with 2 ml/tube of FACS lysing solution (BD). After this second PCR studies incubation, cells were centrifuged (5 min at 625 g), washed once in phosphate-buffered saline (PBS) solution, and
All reactions were performed in a volume of 25 l containing: 1 ϫ PCR buffer (1 mm Tris-HCl pH 8.3, 50 mm KCl, resuspended in 1 ml of PBS.
1% Triton-X 100); 200 mol/l each of dATP, dGTP and dTTP; 2 mol/l dCTP; 1.5 mm After amplification, 3 l of the PCR products were elecwithin the sorted fraction was performed on a FACSort flow cytometer (BD) equipped with a 15-mW Argon ion trophoresed on a 8% polyacrylamide sequencing gel. After electrophoresis, the gels were dried down and exposed to laser tuned at 488 nm. For data acquisition and analysis of cell purity within the fraction of sorted cells, the Lysis II X-ray film at Ϫ80°C for 24-48 h.
Sensitivity
To assess the sensitivity of the PCR-STR method, mixing experiments were performed in which donor peripheral blood cells were mixed with recipient cells in different proportions. Mixtures with decreasing proportions of patient cells (from 50 to 0.1%) were boiled and amplified using the set of primers mentioned above. A minor patient cell population corresponding to 0.1% of the total cells was detected (Figure 1 ).
Results
The median number of CD34 ϩ cells administered to the four patients studied was 5.0 ϫ 10 6 /kg (range, 1.8-7.1). Median follow-up was 16.5 months (range, 14-21). All patients showed a sustained trilineage engraftment through- genitors, most cells coexpressed the HLA-DR antigen, the proportion of HLA-DR − cells being small (mean value 1.54 within the former cell type CD38 Ϫ cells represented only Ϯ 0.54; range, 0.9-2.05%). Figure 2 illustrates the distri-7.2 and 7.3% of the cells, respectively, a much larger probution of CD34 ϩ cells within the whole BM sample from portion was detected within the CD34 ϩ HLA-DR Ϫ cell subone of the patients (Figure 2A ) and the percentage of set (76.2 and 41.7%, respectively) ( Figure 2D ). CD34 ϩ cells within the whole BM sample (Figure 2A ) and the percentage of CD34 ϩ populations according to HLAChimerism studies DR expression ( Figure 2B ). The purity of the CD34 ϩ HLA-DR Ϫ fraction of sorted cells was higher than 94% in all We were able to distinguish donor from patient cells in all cases. Figure 2C shows a representative example from one cases using the panel of STRs described (see Materials and patient. Additionally, in two patients the expression of the methods). vWF microsatellite was useful in the four CD38 antigen was also analyzed within the CD34 ϩ HLApatients studied. (Figure 3) . Moreover, PCR-STR analyses of peripheral blood samples from these patients, performed throughout the observation period post-transplant (Figure 4) , displayed complete donor chimerism ( Figure 5 ).
Discussion
The use of G-CSF-mobilized PBPC for allogeneic transplantation is generating great interest. 13 The clinical advantages of G-CSF-mobilized PBPC over BM in allogeneic transplantation (basically, safer collection of a higher number of CD34 ϩ cells and more rapid hematopoietic recovery) have been described in several reports. One initial concern regarding the use of PBPC for allo- UPN 2, c, UPN 3, d, UPN 4) , was assessed using primers for vWF microsatellite. D = donor; R = recipient.
HLA-DR
Ϫ human BM cells can be transplanted in utero into pre-immune fetal sheep and provide long-term human myeloid and lymphoid hematopoiesis.
17 CD34 ϩ HLA-DR Ϫ cells have also been documented in steady-state human peripheral blood and in the G-CSF-mobilized apheresis products from normal donors. [18] [19] [20] However, in spite of all the above important indirect evidence, a definitive proof of the existence of CD34 ϩ HLA-DR Ϫ donor progenitor cells in In this study, the proportion of CD38 Ϫ cells among the CD34 ϩ HLA-DR Ϫ sorted cells is slightly higher than that reported in the literature. 19, 21 However, it should be taken demonstrated in murine models. 6, 7, 14 In allogeneic transinto account that according to the triple combination of plants, a sustained engraftment and complete donor chimermonoclonal antibodies used, CD38 was combined with ism in recipients of an allo-PBPCT with a long follow-up PE/Cy5 which results in a relatively dim staining as comsupports the concept that LTMRC circulate in the periphpared to the CD3-PE and CD38-FITC conjugates. eral blood. [1] [2] [3] In the autologous setting, the in vivo assessIn conclusion, we have demonstrated, by using the sensiment of LTMRC has been performed by using retroviral 
